StreetInsider.com News Articles

Form 6-K ASCENTAGE PHARMA GROUP For: Oct 22

Thu, 22 Oct 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20261022/27223254.html

Form 6-K ASCENTAGE PHARMA GROUP For: Oct 21

Wed, 21 Oct 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20261021/27217154.html

Ascentage Pharma's lisaftoclax gets China breakthrough designation

Wed, 21 Oct 2026 06:12:36 -0400

Ascentage Pharma Group International (NASDAQ: AAPG) announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) has received a Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Under China's BTD pathway, designated drugs receive priority communications and development guidance from the CDE. Applicants that meet relevant conditions may also apply for Priority Review status and conditional approval when submitting a New Drug Application in China.

Lisaftoclax was approved in China in July 2025 for adult CLL/SLL patients who had

Ascentage Pharma's lisaftoclax gets China breakthrough designation

Wed, 21 Oct 2026 06:12:36 -0400

Lisaftoclax was approved in China in July 2025 for adult CLL/SLL patients who had

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Tue, 20 Oct 2026 19:30:00 -0400

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

BTDs are granted to innovative

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Tue, 20 Oct 2026 19:30:00 -0400

BTDs are granted to innovative

Form 6-K ASCENTAGE PHARMA GROUP For: Oct 15

Thu, 15 Oct 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20261015/27191075.html

Citi Starts Ascentage Pharma Group (AAPG) at Buy

Wed, 14 Oct 2026 05:01:47 -0400

Citi analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Buy rating and a price target of $46.00.

For an analyst ratings summary and ratings history on Ascentage Pharma Group click here. For more ratings news on Ascentage Pharma Group click here.

Shares of Ascentage Pharma Group closed at $15.06 yesterday.

Citi Starts Ascentage Pharma Group (AAPG) at Buy

Wed, 14 Oct 2026 05:01:47 -0400

Citi analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Buy rating and a price target of $46.00.

For an analyst ratings summary and ratings history on Ascentage Pharma Group click here. For more ratings news on Ascentage Pharma Group click here.

Shares of Ascentage Pharma Group closed at $15.06 yesterday.

Citizens Starts Ascentage Pharma Group (AAPG) at Market Outperform

Tue, 13 Oct 2026 03:08:34 -0400

Citizens analyst Silvan Turkcan initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Market Outperform rating and a price target of $35.00.

The analyst comments: “AAPG is a $1,375M market cap commercial-stage, multinational biotechnology company focused on targeted therapies in oncology. AAPG successfully marries expertise in pharmacology and international clinical development strategy and is aiming at high-value indications. We believe key Phase 3 data in MDS (2027) and CML (2027) can provide significant value, which are derisked through approvals in China.

Ascentage Pharma successfully marries expertise in pharmacology and clinical development strategy. 1) Me-better vs. Me-too: AAPG leverages expertise in chemical

Citizens Starts Ascentage Pharma Group (AAPG) at Market Outperform

Tue, 13 Oct 2026 03:08:34 -0400

Citizens analyst Silvan Turkcan initiates coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Market Outperform rating and a price target of $35.00.

Ascentage Pharma successfully marries expertise in pharmacology and clinical development strategy. 1) Me-better vs. Me-too: AAPG leverages expertise in chemical

Ascentage Pharma Group (AAPG) PT Lowered to $33 at JPMorgan

Thu, 08 Oct 2026 08:10:54 -0400

JPMorgan analyst Brian Cheng lowered the price target on Ascentage Pharma Group (NASDAQ: AAPG) to $33.00 (from $46.00) while maintaining a Overweight rating.

Form 6-K ASCENTAGE PHARMA GROUP For: Sep 28

Tue, 29 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260929/27116582.html

Form 6-K ASCENTAGE PHARMA GROUP For: Sep 17

Thu, 17 Sep 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260917/27073223.html

Form 6-K ASCENTAGE PHARMA GROUP For: Aug 20

Thu, 20 Aug 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20260820/26953324.html

Form 6-K ASCENTAGE PHARMA GROUP For: Aug 20

Thu, 20 Aug 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20260820/26953324.html

Form 6-K ASCENTAGE PHARMA GROUP For: Aug 20

Thu, 20 Aug 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20260820/26953324.html

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates